A radioconjugate containing dabrafenib, a tyrosine kinase inhibitor of the V600 mutated version of the B-raf (BRAF) protein and labeled with the positron-emitting isotope fluorine F 18 with potential prostate tumor imaging upon positron emission tomography (PET). Upon administration, the dabrafenib moiety of fluorine F 18 dabrafenib specifically targets and binds to the BRAF V600-mutated form, expressed on tumor cells, thereby allowing the visualization of tumor cells expressing BRAF V600 upon PET. BRAF is constitutively activated in a variety of cancers due to BRAF gene mutations. Check for active clinical trials using this agent.